Compare COE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COE | BOLD |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.1M | 60.8M |
| IPO Year | 2015 | 2024 |
| Metric | COE | BOLD |
|---|---|---|
| Price | $11.46 | $2.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.0K | ★ 196.7K |
| Earning Date | 12-07-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $70.66 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.93 | $0.96 |
| 52 Week High | $52.00 | $3.16 |
| Indicator | COE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 48.92 | 36.03 |
| Support Level | $9.95 | $1.40 |
| Resistance Level | $12.48 | $2.71 |
| Average True Range (ATR) | 0.84 | 0.16 |
| MACD | 0.22 | -0.00 |
| Stochastic Oscillator | 68.34 | 19.77 |
51 Talk Online Education Group is an online education platform in China, with core expertise in English education. The company's mission is to make quality education accessible and affordable. It's online and mobile education platforms enable students across China to take live interactive English lessons with overseas foreign teachers, on demand. The Group operates in geographical areas: Asia-Pacific region; and Other areas, of which it derives maximum revenue from Asia-Pacific.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.